Good MorningEquity markets wobbled again on Wednesday as hotter than expected inflation data capped gains driven by better-than-expected earnings. Reports from the big banks reveal ongoing improvement in the consumer but that news was overshadowed by inflation fears. The producer price index, a leading indicator of consumer inflation, rose 1.0% from the previous month in an acceleration that drove year-over-year inflation to 7.3%.
The news was compounded by testimony from Fed Chief Jerome Powell who says that inflation has accelerated unexpectedly and that high inflation could linger for months. Even so, the FED Chief says there's no expectation for raising interest rates anytime soon. The next big test for the market will come over the next two days with the release of several important economic data points Featured: Is This the New Normal for Gold? (Ad) 
|
Finance | |
While DoorDash (NYSE: DASH) and Airbnb (NASDAQ: ABNB) are among the recent IPOs with the most buzz, they’re actually being trounced in the price-performance department by slightly older IPOs OneMain Holdings (NYSE: OMF), Customers Bancorp (NYSE: CUBI) and InMode (NASDAQ: INMD).
3 Underva... Read the Full Story |
|
From Our Partners | | A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years.
While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million.
One company controls the entire supply chain behind this discovery. | | See the ticker behind this Grand Canyon energy breakthrough now |
|
Markets | |
A friend of mine spent over 10 years in a career that wasn't a great fit. She earned a meager salary, her bosses sighed every time it came time for performance reviews and she didn't advance in her role.
In turn, that affected her earnings, which affected her retirement savings, which affected h... Read the Full Story |
|
Finance | | Consumer borrowing is one of the key forces that drive the economy, which is why it's so great to see borrowing on credit cards and for auto and student loans surging as our financial system continues to recover from the impacts of the pandemic. The Federal Reserve recently reported that U.S. consum... Read the Full Story |
|
From Our Partners | | Palantir, Micron and SanDisk show how fast a stock can become the trade everyone suddenly wants. That's often when investors make their costliest mistake: arriving after the easy part of the move is gone.
A new premium eBook flags 7 stocks that may be worth knowing about before the broader crowd catches on. You don't need to buy any of them - just knowing what's quietly gaining attention can be useful. | | See the 7 stocks on the watchlist while it's still free |
|
Finance | |
A Catch-22 For Wells Fargo
Wells Fargo (NYSE: WFC) is faced with a headwind that has emerged for the entire banking sector. The massive amounts of stimulus pumped into the economy are improving general conditions including consumer health and that is cutting into net interest income. The bank ma... Read the Full Story |
|
Healthcare | |
The Rebound Is On For Organigram
Organigram (NASDAQ: OGI), and the entire Canadian cannabis market, have been struggling in the wake of the COVID-19 pandemic. It's not that demand has evaporated so much as it is that stores have been closed and people can't get the product. But that's changing. C... Read the Full Story |
|
From Our Partners | | Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies.
Dr. Mark Skousen, who met Musk in person and called the SpaceX listing months early, says he has identified all three targets in what he calls Elon's $2.1 Trillion Hit List.
See the three companies before the rumors become headlines. | | Get the details on all three companies now |
|
Finance | |
In the universe of bank stocks, Bank of America (NYSE:BAC) is considered to be one of “the rest.” That is, that many investors view JPMorgan Chase (NYSE:JPM) and Goldman Sachs (NYSE:GS) as “the best.” Anything else pales in comparison.
I’m not going to debate that ... Read the Full Story |
|
Industrials | |
Fastenal Reports As-Expected Results
We don't want to imply that Fastenal (NASDAQ: FAST) is in bad shape because it's not. The problem that we are faced with is the same one that we were faced with when the company reported Q1 results. The results are 100% as expected, revenue is supported by pr... Read the Full Story |
|
Consumer Staples | | Consumer staple stocks like PepsiCo (NASDAQ:PEP) can be a great addition to any long-term portfolio, as they are known to hold up well in recessions and provide consistent dividend increases over the years. While they might not be as exciting as some of the cutting-edge tech stocks that have been dr... Read the Full Story |
|
Markets | |
I recently became part of the wave of people leaving their jobs during the "Great Resignation," the mass exodus of workers from their regular nine-to-five jobs. We must all think the grass is greener on the other side, huh? (You and I aren't the only ones. You can find 6 million more gig workers t... Read the Full Story |
|
Consumer Discretionary | |
Clothing retailers including Revolve Group (NYSE: RVLV), Boot Barn (NYSE: BOOT) and Lands’ End (NASDAQ: LE) are trading at new highs as customers spruce up long-neglected wardrobes.
As you might imagine, walk-in traffic is increasing at retail locations, but online ordering took off and bus... Read the Full Story |
|
The Early Bird Stock Of The Day Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany. | | View Today's Stock Pick |
|
